Evidence map›Paper›PMID 30297122›Full record

ArticleVaccine2018

Impact of maternally derived pertussis antibody titers on infant whole-cell pertussis vaccine response in a low income setting.

Romesa Ibrahim, S Asad Ali, A Momin Kazi, Arjumand Rizvi, L Beryl Guterman, Robert A Bednarczyk, Ellie Kim, SoHee Park, Simon Paulos, Amilia Jeyachandran and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Romesa IbrahimDepartment of Paediatrics and Child Health, Aga Khan University, Karachi, Pakistan.
S Asad AliDepartment of Paediatrics and Child Health, Aga Khan University, Karachi, Pakistan. Electronic address: asad.ali@aku.edu.
A Momin KaziDepartment of Paediatrics and Child Health, Aga Khan University, Karachi, Pakistan.
Arjumand RizviDepartment of Paediatrics and Child Health, Aga Khan University, Karachi, Pakistan.
L Beryl GutermanDepartment of Global Health, Emory University, Atlanta, Georgia.
Robert A BednarczykDepartment of Global Health, Emory University, Atlanta, Georgia; Department of Epidemiology, Emory University, Atlanta, Georgia; Department of Emory Vaccine Center, Emory University, Atlanta, Georgia.
Ellie KimMPIR Laboratory, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
SoHee ParkMPIR Laboratory, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Simon PaulosMPIR Laboratory, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Amilia JeyachandranMPIR Laboratory, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Divya PatelMPIR Laboratory, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Yamini GorantlaMPIR Laboratory, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Emily WongMPIR Laboratory, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Gowrisankar RajamMPIR Laboratory, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Jarad SchifferMPIR Laboratory, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Saad B OmerDepartment of Global Health, Emory University, Atlanta, Georgia; Department of Epidemiology, Emory University, Atlanta, Georgia; Department of Pediatrics, Emory University, Atlanta, Georgia; Department of Emory Vaccine Center, Emory University, Atlanta, Georgia.
Centers for Disease Control and Prevention · USAga Khan University · PKEmory University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMaternal vaccines against pertussis are not yet recommended in the developing world. Besides unclear burden estimates, another concern is that transplacental transfer of maternal pertussis antibodies could result in attenuation of the immune response to whole cell pertussis (DTwP) primary vaccination series in infants. This study was taken up to determine whether higher levels of maternal pertussis antibodies attenuate immune response of infants to DTwP vaccination series given at 6-10-14 weeks of age. METHODOLOGY: A total of 261 pregnant women and their infants from four low-income settlements in Karachi, Pakistan were enrolled in this study. The study endpoints were infant antibody titers for Pertussis toxin (PTx), Filamentous hemagglutinin antigen (FHA), Pertactin (PRN) and Fimbriae type 2/3 (FIM) - from birth through 18 weeks of age. Cord blood or pre-vaccine pertussis antibody titers indicate the concentration of maternal antibodies transferred to infants. Linear regression models were used to determine the association between higher maternal antibody titers and infant immune response to DTwP vaccine. Geometric Mean Ratio (GMR) was calculated as the ratio of infant antibody titers at specified time points against the maternal antibody titers at the time of delivery.

resultsAt eighteen weeks of age, the adjusted β regression coefficient for PTx was 0.06 (95% CI: -0.49-0.61), FHA 0.02 (95% CI: -0.26 -0.29), PRN 0.02 (95%CI -0.38- 0.43), and FIM 0.17 (95%CI: -0.21-0.54). Among infants who received at least two doses of DTwP vaccine, higher maternal antibody titers did not have any attenuating effect on infant post-immunization antibody titers against all four pertussis antigens.

conclusionMaternal pertussis antibodies did not attenuate infant's immune response to pertussis antigens in DTwP primary vaccine given at 6-10-14 weeks of age.

Indexed as

Immunity, Maternally-AcquiredAdolescentAdultAntibodies, BacterialCohort StudiesDeveloping CountriesDiphtheria-Tetanus-Pertussis VaccineFemaleHumansImmunization ScheduleInfantInfant, NewbornMalePakistanPregnancyTreatment OutcomeAntibodies, BacterialDiphtheria-Tetanus-Pertussis VaccineDTwPImmune bluntingImmunogenicityMaternal vaccinationPertussis vaccine

Identifiers

PMID30297122
PMCPMC6219892
OpenAlexW2895430492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.